This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Small-Cap Winners & Losers

Corillian (CORI - Get Report) rocketed more than 45% after the company, which sells Internet-based software to financial services firms, agreed to sell itself to electronic payment processor CheckFree (CKFR) for $5.15 a share, or roughly $245 million. The deal will likely close around June 1. Oregon-based Corillian was rising $1.57 to $5.02. Checkfree shares were dipping 42 cents, or 1%, to $41.20.

Cumberland Resources (CLG) shot up 23.3% on word fellow Canadian gold miner Agnico-Eagle Mines (AEM) will buy it in a stock swap that values Cumberland around $608.9 million. Cumberland was up $1.38 to $7.33. Agnico-Eagle was losing 84 cents, or 2%, to $40.38.

SPSS (SPSS) jumped after the analytical-software company said fourth-quarter operating income spiked 36% to $11.7 million from a year ago; excluding a large noncash income tax charge, per-share earnings totaled 43 cents. Revenue rose 14% year over year to $71.1 million. Analysts polled by Thomson Financial were looking for 34 cents a share on revenue of $67.5 million. Shares of the Chicago-based company were up $4.91, or 15.4%, to $36.79.

San Diego, Calif., biotech Halozyme Therapeutics (HTI) announced an expansion of its existing Hylenax-recombinant agreement with medical-products maker Baxter (BAX). The deal now allows Baxter to use Hylenax with its small-molecule drugs, for which the former will pay Halozyme $10 million upfront and buy $20 million worth of Halozyme equity, in addition to possible milestone payments and royalties. Halozyme shares were gaining $1, or 12.7%, to $8.85. Baxter was edging up 17 cents to $50.11.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRI $105.87 -1.50%
CORI $5.23 10.00%
WGA $0.36 2.86%
AAPL $95.28 1.80%
FB $117.72 -0.72%


Chart of I:DJI
DOW 17,771.66 -119.50 -0.67%
S&P 500 2,063.80 -17.63 -0.85%
NASDAQ 4,773.2230 -44.3710 -0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs